KYMR

115.3103.42%
JW

Jeffrey W. Albers

Independent Chairman of the Board

Mr. Jeffrey W. Albers, also known as Jeff, J.D. & M.B.A., is Venture Partner of Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). from 2024. He has been Chairman of the Board at Triveni Bio Inc. since December 2023. He serves as Executive Chairman of Scorpion Therapeutics, Inc. since January 4, 2024. He has been Independent Director of Spyre Therapeutics, Inc. since November 28, 2023 and also has been its Chairman of the Board since May 2024. He serves as Independent Chairperson at MoMa Therapeutics, Inc. since February 2023. He served as Independent Director at Dianthus Therapeutics Inc. until September 11, 2023. He served as Chairman of the Board at Blueprint Medicines Corporation since December 31, 2022 until July 18, 2025 and served as its Executive Chairman since June 2021 until December 31, 2022. He has been Independent Director of Kymera Therapeutics, Inc. since July 2020. He had been the Chief Executive Officer and President of Blueprint Medicines Corp since July 2014 until April 4, 2022. Mr. Albers had been President of Algeta US at Algeta ASA since January 15, 2012 until April 2014. He worked closely with Algeta's senior management as part of the executive management team to enable Algeta's US commercial operations; the plans for which include the phased building of a sales force and a marketing and medical affairs team aHead of the launch of Alpharadin (radium-223 chloride) for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases, pending approval. Prior to Algeta, he served at Genzyme (Sanofi), where he spent few years in senior commercial and corporate development positions and also served as its Vice President of US Hematology & Oncology Business unit from July 2005 to November 2011. In this role, Mr. Albers was P&L responsible for a USD 250 m business that included multiple marketed products along with a pipeline of products to treat hematologic and solid tumor malignancies. He built and led a 135-person team spanning sales, operations, marketing, managed care, pricing and reimbursement, training and medical affairs. He was also involved in evaluating in-licensing opportunities. Mr. Albers played a key role in the successful US launch of Mozobil and integrating Campath and Leukine into the portfolio involving a significant field force restructuring. Prior to Genzyme, he spent few years, from 2000 to 2005 as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo, where he focused on life sciences transactional work. He has prior experience as a sales Representative for Pfizer, Inc. He is on the Board of Advisors for Life Sciences Cares. He was a Director of Blueprint Medicines Corp since July 2014 until July 18, 2025. He is also a venture Partner at Atlas Ventures and serves on the Board of advisors for Life Sciences Cares. He has been Independent Director of Magenta Therapeutics, Inc. since July 2017. He holds a B.Sc. in Marketing from Indiana University and a law degree (J.D.) and MBA degree from Georgetown University (Washington, DC). He currently serves on the Board of Directors of Eastern New England Chapter of the American Can.

Positions